Business
Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia
Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announces completion of patient enrollment of an investigator-initiated, proof-of-concept, open-label study with low-dose IL-2 and CTLA4-Ig combination treatment in patients with Frontotemporal Dementia (FTD). The study is led by Dr. Alireza Faridar and Dr. Stanley Appe
About this update from Coya Therapeutics, Inc.
[{"type":"text","content":"Following the positive interim results in 5 patients announced earlier this year, a total of 9 patients have been enrolled as planned","length":133,"tagName":"p","attribs":{}},{"type":"text","content":"The study is progressing according to protocol, and no safety issues have been reported","length":87,"tagName":"p","attribs":{}},{"type":"text","content":"Study completion is anticipated in Q4 2025 with topline to follow","length":65,"tagName":"p","attribs":{}},{"type":"text","content":"HOUSTON, Sept. 29, 2025 /PRNewswire/ -- Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announces completion of patient enrollment of an investigator-initiated, proof-of-concept, open-label study with low-dose IL-2 and CTLA4-Ig combination treatment in patients with Frontotemporal Dementia (FTD). The study is led by Dr. Alireza Faridar and Dr. Stanley Appel at the Houston Methodist Neurological Institute (Houston, TX) with funding from The Peggy and Gary Edwards Endowment Fund. Study patients received subcutaneously administered CTLA4-Ig, followed by a 5-day course of low-dose IL-2 every four weeks, for a total of 22 weeks of dosing and follow-up.","length":862,"tagName":"p"},{"type":"image","alt":"Coya Therapeutics Logo (PRNewsfoto/Coya Therapeutics, Inc.)","displaySize":"","headline":null,"caption":"Coya Therapeutics Logo (PRNewsfoto/Coya Therapeutics, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":166,"url":"https://media.zenfs.com/en/prnewswire.com/fb38d4ecdc4a3b01b49e80cb14dc14c0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6YOAPSIXWRSkBXjtK9S80A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI5MztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/fb38d4ecdc4a3b01b49e80cb14dc14c0","width":400,"height":166}},"href":"https://mma.prnewswire.com/media/2748215/Coya_Therapeutics_Transparent_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Following the positive interim results of 5 patients announced in April 2025, the study has enrolled an additional 4 patients for a total of 9 FTD patients. The trial is progressing according to the study protocol and no serious adverse events ...